ethcalon
ethcalon operates at the boundary between chronos and kairos. What has real value exists before any market learns to price it. The firm designs the crossing.
Something real exists before it can be priced. ethcalon exists to deliver it to the world without distorting what made it real.
We work with enterprises that have built something real. In science, in creative work, in food. The market has not yet learned to see it. The work is the same in every case: translate that reality into a form the right counterparties can recognize, act on, and value. Strategy, deal structuring, and capital formation are the instruments.
The firm operates without accumulation. No layers between the work and the person doing it. That is a structural choice, not a limitation.
ethcalon is forming its US entity in 2026. New York.
Shinji Otsubo
Founder & Architect
As Head of Global Business Development at FRONTEO's Life Science AI division, Shinji leads licensing negotiations and deal structuring for AI-driven drug discovery platforms. The transactions are cross-border and in the range of tens to hundreds of millions of dollars. The counterparties are global pharmaceutical companies.
Earlier in his career, he served as President and CEO of one of Japan's largest game development studios. He later served as a board director within a major entertainment and content distribution group, where he was responsible for corporate and business strategy, including IR and portfolio planning. Since 2020, he has also operated his own company, advising prominent animation production companies on management and strategic planning. Across these roles, he has worked at the intersection of creative production, distribution, and capital, with experience spanning M&A transactions, TOB projects, post-merger integrations, and joint venture formations across Japan, China, and the United States.
Shinji holds a Master of Arts from the Fletcher School of Law and Diplomacy at Tufts University and an MBA from HEC Paris (dual-degree).
LinkedIn Profile